Nasal Versus Oral Midazolam Sedation in Routine Pediatric Dental Care: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Nasal Versus Oral Midazolam Sedation in Routine Pediatric Dental Care (NCT02679781), a randomized na study. The primary outcome is Number of Participants Compliant With Oral or Nasal Midazolam Administration.

2. Clinical Question

The registry frames the study as a comparison of the efficacy of oral syrup and nasal-atomizer midazolam, with specific interest in medication acceptability, behavior, onset time, and maximum working time. The primary outcome focuses on whether and how the medication was accepted at administration. Behavior during dental treatment is listed as a secondary outcome. Although the objective description mentions onset and working time, outcome details and results for those measures are not reported in the registry record.

The question is about the route of midazolam administration within a dental-care sedation setting, not about midazolam compared with no sedation. Both arm descriptions include the same stated nitrous oxide/oxygen mixture during treatment. The record does not establish whether other aspects of care were identical, how acceptability categories were to be interpreted in a comparative analysis, or whether the trial was designed to determine a preferred route.

No primary outcome counts, effect estimate, uncertainty interval, or statistical comparison is reported. Consequently, the registry record identifies the intended comparison but does not show whether compliance differed between the arms or how precisely any difference was estimated.

3. Trial Design

The registry describes a randomized, single-masked, parallel-group trial. Random allocation assigns participants to an arm by chance, while a parallel design means the assigned intervention is the treatment route for that participant rather than a sequence of both routes. The record does not report the allocation procedure, whether allocation was concealed, or who was masked. The label single-masked does not by itself identify which people involved in treatment, assessment, or analysis were unaware of assignment.

The planned arms were oral sedation with 0.5mg/kg oral midazolam and nasal sedation with 0.2mg/kg nasal midazolam. The nasal formulation was described as administered with a nasal atomizer, while the oral formulation was described as syrup. Both arm descriptions specify 50% nitrous oxide/ 50% oxygen via nasal hood during dental treatment. The trial therefore compares two routes and associated doses in the described care setting; it does not compare sedation with no sedation.

The condition is listed as conscious sedation, the phase is listed as NA, and the sponsor is Hadassah Medical Organization. The registry records a start date of 2017-03-28, primary completion on 2020-12-15, a completed status, and enrollment of 70. Recruitment sites, eligibility criteria, participant age details, the allocation ratio, and the basis for the enrollment target are not reported in the registry record.

The primary outcome is compliance with oral or nasal midazolam administration, assessed at the time of administration and recorded immediately by an investigator. The record also lists Behavior During Dental Treatment as a secondary outcome. It does not provide outcome results or analyses for either measure. Although the study objectives mention onset time and maximum working time, the registry entries available do not specify their measurement definitions or report their results.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants Compliant With Oral or Nasal Midazolam Administration, measured over the compliance in taking the medication will be assessed at the time of administration and recorded immediately..

The primary endpoint concerns compliance with taking the assigned medication. An investigator was to assess compliance at the time of administration and record it immediately. The categories were willingly, coaxed, forced, or failed (not administered). These categories describe different degrees of acceptance and whether administration occurred. They can therefore provide information about the practical acceptability of each route in the study setting, beyond a simple record that medication was or was not administered.

The endpoint is relevant to a comparison of oral syrup with nasal administration because the route itself may shape a child’s response to receiving medication. Recording the observation immediately is intended to capture the administration experience rather than relying on a later recollection. The registry, however, does not report instructions for applying the categories, whether assessors used a standardized procedure, or how observations were to be combined for statistical analysis.

The outcome title refers to the number of participants compliant with administration, while the description specifies four recorded categories. A single binary comparison cannot be reconstructed from those categories without a rule defining which categories count as compliant. The registry record does not report such a rule or category-specific results. Its outcome classification describes a count of participants with an event, but the available result information does not establish the event definition used in an analysis.

Behavior during dental treatment is separately listed as a secondary outcome. The registry does not report its measurement method or results. Thus, the primary endpoint addresses immediate medication acceptance, not by itself behavior during the procedure, onset, duration of effect, or overall efficacy.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does randomization contribute?

Randomization assigns participants to study arms using chance. In general, this approach helps prevent treatment assignment from being determined by participant characteristics or clinician preference. If implemented well, it supports a causal comparison between assigned interventions, subject to how outcomes are measured, who is included in the analysis, and how missing observations are handled. It does not guarantee that groups will be identical, nor does the word randomized alone establish that the allocation sequence was concealed. The registry does not describe the sequence-generation or concealment procedures.

The trial is also described as parallel-group. In general, participants in such a design receive their assigned intervention rather than switching between study treatments. This avoids some interpretive issues that arise when outcomes under one treatment may be affected by earlier exposure to another. The record does not provide details about treatment adherence after administration or any departures from assignment.

What does single masking mean?

Masking is intended to reduce the influence of treatment knowledge on care, assessment, or reporting. The registry identifies the study as single-masked but does not state who was masked. It is therefore not possible to determine whether masking applied to participants, investigators, outcome assessors, or another group. The routes are visibly and practically different, but the registry does not describe how masking was implemented or whether it was maintained. Since the primary outcome is an investigator-recorded assessment of acceptance at administration, knowing or guessing the assigned route could be relevant to the assessment process. The available record does not establish whether this occurred.

How should the primary endpoint be understood?

The primary measure is recorded as a count of participants, but its description calls for four categories: willingly, coaxed, forced, or failed (not administered). A count outcome needs a clear event definition before it can be interpreted as a binary outcome. For example, an analysis would need to specify which category or categories represent the event being counted. No such rule or category-by-arm results are reported in the registry record. It would be inappropriate to combine categories or recast the outcome as a success rate without that information.

More generally, a categorical outcome can be analyzed by comparing the distribution across categories or by defining a clinically meaningful binary contrast in advance. Those approaches answer different questions. A distributional comparison asks whether the pattern across all recorded responses differs, while a binary comparison asks about the frequency of a specified event. The registry gives no analysis method, so it is not possible to determine which approach was planned or used.

What can an effect estimate and confidence interval tell readers?

In general, an effect estimate quantifies the contrast between groups for a specified outcome. A confidence interval expresses statistical uncertainty around that estimate under the assumptions of the method. A narrow interval indicates greater precision than a wide interval, but an interval does not correct for bias in measurement, missing outcomes, or an inappropriate analysis. An estimate should be interpreted together with its outcome definition and analysis population. The registry record does not report an estimate or confidence interval for the primary endpoint, so neither the direction nor precision of an effect can be assessed.

A p-value, when reported, evaluates how compatible the observed data are with a specified null model under the test’s assumptions. It does not measure the size or importance of an effect, and it is not a substitute for an estimate and interval. No primary comparison or p-value is reported. It is therefore not possible to characterize the primary result as statistically significant or not statistically significant.

Why does the analysis plan matter?

A prespecified analysis plan explains how outcomes will be defined, how groups will be compared, which participants will be analyzed, and how missing values or protocol deviations will be handled. Such choices matter because different defensible methods can yield different summaries, especially for a multi-category endpoint. The registry record does not report a statistical analysis plan, an adjusted model, an analysis population, or an approach to missing data. It lists zero analyses. The absence of a posted analysis means the intended methods and any completed inferential analysis cannot be evaluated.

For a count of participants with an event, a simple comparison may be possible if the event and denominator are clearly defined. More complex approaches may be appropriate depending on the endpoint structure and design. General statistical methods should not be selected after seeing outcomes without considering the risk of data-driven choices. Here, neither a method nor results are documented, so recalculation from summary statistics is not possible. No recalculated comparison is available, and there is no basis for checking whether a sponsor analysis differs from a simple unadjusted calculation.

How should planning calculations be read?

In general, sample-size planning asks how many participants would be needed to detect a chosen effect under stated assumptions. The registry’s planning description refers to a two-sided significance level of 0.05, equal allocation between arms, and a normal approximation, with the target effect expressed as a fraction of the observed effect. It distinguishes participant counts per arm for outcomes other than time-to-event outcomes. Such planning illustrations are conditional on their assumptions and are not observed trial findings or observed power.

The registry record does not report a sample-size justification for the trial’s original design. It also does not report an observed primary effect from which a planning illustration could be interpreted in this record. Any sample-size planning value should not be read as evidence that the trial had a particular chance of detecting an effect, nor as a substitute for the outcome estimate and its uncertainty.

Over-dispersion is a general issue when observed variation in count data exceeds what a chosen statistical model assumes. If present, an inadequately modeled variance can make uncertainty estimates too small. That concept does not establish that over-dispersion occurred in this trial: the primary measure is described as a participant count with categorical administration responses, and no relevant fitted model or data distribution is reported.

10. Multiplicity, Missing Data and Analysis Populations

The registry identifies a primary outcome and lists Behavior During Dental Treatment as a secondary outcome. Its study objectives also mention acceptability, behavior, onset time, and maximum working time. The record does not explain how the primary and secondary measures were prioritized in testing, whether any multiplicity adjustment was planned, or whether the objective areas beyond the named outcome measures were analyzed. When several outcomes or comparisons are examined, the chance of at least one apparently unusual result can increase; in general, a prespecified strategy helps readers distinguish primary inference from exploratory findings. No such strategy is reported.

The registry lists two outcome measures and zero analyses. It does not report estimates, test results, or a statistical analysis plan. There is therefore no basis to assess whether the analyses matched the listed outcome hierarchy or whether additional comparisons were performed.

Missing-data methods are not reported in the registry record. The primary outcome description includes failed (not administered) as a recorded category, but this is a defined response category, not necessarily a missing observation. The record does not say how an unrecorded assessment, withdrawal, or other unavailable outcome would be handled. It also does not describe protocol deviations or treatment discontinuation.

Analysis populations are not reported. The registry does not state whether the primary comparison was to include all randomized participants, only those who received the assigned medication, or another defined group. Such choices affect interpretation because they determine which participants contribute to each result. The enrollment entry and adverse-event denominators do not resolve the analysis population for the primary endpoint.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry’s adverse-event summary lists the oral-sedation group with 37 at risk, 0 serious adverse events, 0 other adverse events, and 0 deaths. The nasal-sedation group is listed with 33 at risk, 0 serious adverse events, 0 other adverse events, and 0 deaths. No top serious-event terms are listed.

These are descriptive entries in the registry record. They indicate that the posted summary contains zero events in each listed category for both groups. They do not establish that every possible adverse effect was actively assessed, that all events were captured, or that there is no safety difference between routes. The registry does not report event definitions, ascertainment methods, seriousness criteria, follow-up duration, or a statistical comparison of safety.

The at-risk figures belong to the adverse-event summary. They should not be assumed to be the denominators for the compliance outcome, for which no category counts or analysis population are reported. A zero count is also not an estimate of zero risk with perfect certainty; in general, the precision of a risk estimate depends on the amount and structure of the observed data. No uncertainty interval is reported for these safety entries.

Accordingly, the figures support only a narrow statement about what the registry posted: no serious events, other events, or deaths are recorded in these summaries. They do not justify a broader conclusion about comparative safety or the absence of harms.

12. What the Result Does, and Does Not, Mean

The record gives a clear description of the intended treatment contrast: oral midazolam as syrup versus nasal midazolam using a nasal atomizer, with the stated doses and the same described nitrous oxide/oxygen mixture during dental treatment. It also identifies an immediate administration-compliance outcome and a secondary behavior outcome. These details help define the clinical question and the setting in which it was to be studied.

What the record does not provide is the information needed to answer that question empirically. There are no reported compliance category counts, no comparison of the primary outcome, and no estimate of the size or precision of an effect. The registry also does not report behavior results or results for the objectives concerning onset time and maximum working time. The completed status is not itself evidence of a particular finding.

The absence of a result is not evidence that the routes produced the same response. It is also not evidence that one route was more acceptable. Without outcome data, neither the direction nor the magnitude of a difference can be described. Without uncertainty estimates, the precision of any difference cannot be judged. The record does not show whether the study met a prespecified criterion for success, because no such criterion or analysis is reported.

Nor does the safety summary establish that either route is free of risk. It reports zero serious and other adverse events and zero deaths in each listed group, but the record does not describe the methods or duration of event monitoring. These entries should not be generalized beyond the posted summary.

The most defensible interpretation is therefore about the scope and completeness of the registry record: it documents a randomized comparison and the intended outcomes, but it does not publish the results needed to estimate comparative acceptability, behavior, or other study objectives. Clinical claims about relative benefit or harm cannot be drawn from the available record.

13. Why This Trial Matters Statistically

This trial is statistically interesting because the primary outcome is not simply whether medication was received. The investigator was to distinguish willingly, coaxed, forced, and failed administration. These categories preserve detail about the experience of receiving medication, but they also require a clear analysis strategy. A single count of compliant participants cannot be interpreted without knowing how the categories were classified. The registry does not report that rule or the results, making the endpoint’s operational meaning central to evaluating the trial.

The comparison also illustrates why treatment labels and analysis populations must be kept distinct. The enrollment entry is 70, while the adverse-event summaries use group-specific at-risk figures. Those safety denominators do not automatically identify who contributed to the primary outcome analysis. A reader needs outcome-specific denominators and a description of exclusions to understand what a group comparison represents.

Randomization and masking are important design features, but their labels are not enough to assess implementation. The registry calls the study randomized and single-masked, yet does not describe sequence generation, concealment, or who was masked. These details matter particularly when the primary assessment is an investigator’s rating at the point of administration and the routes can be distinguished in practice.

Finally, the record distinguishes the planned question from the evidence needed to answer it. A completed status and a description of objectives do not provide an effect estimate. Without reported results, uncertainty, analysis methods, and missing-data handling, the central statistical interpretation remains unresolved. The case underscores that transparent outcome reporting is necessary to move from a trial design to a reliable comparison.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

A major limitation of the registry record is that it does not report primary or secondary outcome results. The primary measure is described through four response categories, but there are no category counts, event definitions for a binary analysis, or comparative estimates. The registry also does not report results for behavior during dental treatment, despite listing it as a secondary outcome. Onset time and maximum working time appear in the study objectives, but measurement details and results for these objectives are not reported in the registry record.

The description of the primary endpoint leaves important interpretive questions open. It says compliance was assessed by an investigator and recorded immediately, but does not report how the categories were applied, whether assessors received standardized instructions, or how disagreements were resolved. The single-masked designation does not identify who was masked, and the record does not describe how masking was implemented. These omissions prevent assessment of potential influence on a subjective administration rating.

Participant eligibility criteria, age characteristics, baseline data, recruitment locations, allocation concealment, and the allocation ratio are not reported. The record lists enrollment of 70, but does not report a sample-size justification or clarify how this enrollment relates to the group-specific safety denominators. Analysis populations, missing-data procedures, protocol deviations, and statistical methods are also not reported.

For safety, the posted summary gives zero counts for serious events, other events, and deaths, but does not specify the event definitions, surveillance procedures, or follow-up period. The absence of those details limits interpretation of the scope of safety reporting. Overall, these limitations concern both the incompleteness of the results and the lack of methodological detail needed to assess how those results would have been generated.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Nasal Versus Oral Midazolam Sedation in Routine Pediatric Dental Care — NCT02679781.
• Registry record last updated 2022-01-14; status last verified 2022-01.
• Results first posted 2022-01-14.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT02679781 is a completed randomized, single-masked, parallel-group trial sponsored by Hadassah Medical Organization. It compares oral midazolam syrup at 0.5mg/kg with nasal midazolam at 0.2mg/kg administered using a nasal atomizer. Both arm descriptions specify 50% nitrous oxide/ 50% oxygen via nasal hood during dental treatment. The registry lists enrollment of 70 and a phase of NA.

The primary outcome concerns compliance with medication administration, recorded as willingly, coaxed, forced, or failed (not administered). Behavior During Dental Treatment is listed as a secondary outcome. The registry reports no analyses and does not provide outcome results, effect estimates, confidence intervals, or statistical test results. Its adverse-event summary records zero serious events, zero other events, and zero deaths in both groups, with 37 at risk in the oral-sedation group and 33 in the nasal-sedation group.

The record defines the intended comparison but does not provide enough results to estimate comparative effectiveness, acceptability, behavior, or precision.